Vaxxas Lands $20,000,000 Series B Financing

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    47 Thorndike Street Cambridge, MA 02141 USA
  • Company Description
    Vaxxas is focussed on enhancing the performance of existing and next generation vaccines through the development and commercialization of the company’s novel vaccine delivery technology – the Nanopatch.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    The raise comes as Vaxxas is hitting the most critical point in its development. Later this year, it’ll finally begin testing its technology in humans.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy